Delivery Order SPE2DB22D3501-SPE2DB25FVD74

Award Date 4/3/25
Potential Completion Date 4/4/25
Potential Value $1.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,566,661,577 units of febuxostat 40 mg tablets. The award, valued at $2,066.16, is a Firm Fixed Price Delivery Order with an ultimate completion date of December 10, 2024. The contract has no set-aside designation, indicating open competition. AmerisourceBergen, a for-profit organization registered in the System for Award Management...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $1,515.32 firm fixed-price delivery order is for the supply of febuxostat 40 mg tablets. This order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of febuxostat 40 mg tablets. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $4,075.98 and an ultimate completion date of April 14, 2025. There was no set-aside designation for this award. AmerisourceBergen Drug Corp is a major pharmaceutical distributor that holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,883.24, is for the delivery of 4,567,985,060 units of Febuxostat 40 mg tablets. The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 22, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to supply 4,566,025 units of the drug febuxostat 40 mg tablets. The delivery order contract, valued at $1,624.68, has a firm fixed price and an ultimate completion date of October 7, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, identified as SPE2DB20D1100|SPE2DB25FC2J2, is a delivery order for the supply of 40 mg Febuxostat tablets. The contract has a ceiling value of $1,232.56 and is a firm fixed-price contract with a completion date of May 12, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., to provide Febuxostat 40 mg tablets. The $10,771.20 firm-fixed-price delivery order has a period of performance through February 6, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a comprehensive...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Febuxostat 80 mg tablets. The $1,328.20 firm fixed-price award has a period of performance through July 2024. Amerisourcebergen provides a wide range of essential pharmaceutical and medical products to federal agencies and healthcare programs, including military treatment facilities and veterans' hospitals. This delivery order is part of a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,798.85 firm-fixed-price delivery order is for the supply of Febuxostat 40 mg tablets, a medication used to treat gout. The contract has an ultimate completion date of February 26, 2025 and was awarded on February 25, 2025. This contract is not designated as a set-aside. AmerisourceBergen holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,116.62 firm fixed-price delivery order is for the supply of FEBUXOSTAT 40 MG TABLET 30S, a medication used to treat gout. The contract has an ultimate completion date of March 3, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB25FVD74
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,633.92, is a delivery order contract with a firm fixed price for the supply of febuxostat 40 mg tablets. The contract has an ultimate completion date of April 4, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 7/3/25, 2:50 PM